Treatment and outcome characteristics
| Characteristic . | All patients (N = 71) . | RT only (n = 36) . | Combined therapy (n = 29) . | RT-only vs combined therapy, P . | Systemic therapy (n = 6) . |
|---|---|---|---|---|---|
| Treatment | |||||
| Systemic only | 6 (9) | ||||
| Radiation only | 36 (51) | ||||
| Combined | 29 (41) | ||||
| Treatment era | |||||
| Before 2000 | 8 (11) | 6 (17) | 2 (7) | .444 | 0 |
| 2000–2010 | 30 (42) | 14 (39) | 11 (38) | 5 (83) | |
| 2011–2017 | 33 (47) | 16 (44) | 16 (55) | 1 (17) | |
| Systemic therapy (n = 35) | |||||
| R-ABVD | 5 (7) | 4 (14) | 1 (17) | ||
| R-CHOP | 22 (31) | 19 (66) | 3 (50) | ||
| Rituximab | 5 (7) | 3 (10) | 2 (33) | ||
| Other | 3 (4) | 3 (10) | |||
| RT (n = 65) | |||||
| EFRT | 12 (17) | 9 (25) | 3 (10) | .088 | |
| IFRT | 20 (28) | 13 (36) | 7 (24) | ||
| ISRT | 33 (47) | 14 (39) | 19 (66) | ||
| RT (n = 65) | |||||
| 3-Dimensional | 39 (60) | 27 (75) | 12 (41) | .010 | |
| Intensity-modulated RT | 26 (40) | 9 (25) | 17 (59) | ||
| Radiation dose (n = 65) | |||||
| Median (range), Gy | 30.6 (21.6-40.0) | 36 (30-40) | 30.6 (21.6-40) | ||
| >30.6 Gy | 32 (49) | 26 (72) | 6 (21) | <.001 | |
| ≤30.6 Gy | 33 (51) | 10 (28) | 23 (79) | ||
| Death | |||||
| Yes | 6 (8) | 3 (8) | 2 (7) | 1 (17) | |
| No | 65 (92) | 33 (92) | 27 (93) | 5 (83) | |
| Relapse or progression | |||||
| Yes | 15 (21) | 8 (22) | 5 (17) | 2 (33) | |
| No | 56 (79) | 28 (78) | 24 (83) | 4 (67) | |
| Local relapse | |||||
| Yes | 2 (3) | 0 | 0 | 2 (33) | |
| No | 69 (97) | 36 (100) | 29 (100) | 4 (67) | |
| Distant relapse | |||||
| Yes | 13 (18) | 8 (22) | 5 (17) | 0 | |
| No | 58 (82) | 28 (78) | 24 (83) | 6 (100) | |
| Transformation | |||||
| Yes | 2 (3) | 1 (3) | 1 (3) | .876 | 0 |
| No | 69 (97) | 35 (97) | 28 (97) | ||
| Second malignancy | |||||
| Yes | 8 (11) | 3 (8) | 5 (17) | .277 | 0 |
| No | 63 (89) | 33 (92) | 24 (83) | 6 (100) | |
| Median follow-up (95% CI), y* | 6.1 (5.0-7.2) | 6.1 (3.3-8.9) | 4.4 (0.42–8.4) | .174 | 7.5 (4.0-11.0) |
| Characteristic . | All patients (N = 71) . | RT only (n = 36) . | Combined therapy (n = 29) . | RT-only vs combined therapy, P . | Systemic therapy (n = 6) . |
|---|---|---|---|---|---|
| Treatment | |||||
| Systemic only | 6 (9) | ||||
| Radiation only | 36 (51) | ||||
| Combined | 29 (41) | ||||
| Treatment era | |||||
| Before 2000 | 8 (11) | 6 (17) | 2 (7) | .444 | 0 |
| 2000–2010 | 30 (42) | 14 (39) | 11 (38) | 5 (83) | |
| 2011–2017 | 33 (47) | 16 (44) | 16 (55) | 1 (17) | |
| Systemic therapy (n = 35) | |||||
| R-ABVD | 5 (7) | 4 (14) | 1 (17) | ||
| R-CHOP | 22 (31) | 19 (66) | 3 (50) | ||
| Rituximab | 5 (7) | 3 (10) | 2 (33) | ||
| Other | 3 (4) | 3 (10) | |||
| RT (n = 65) | |||||
| EFRT | 12 (17) | 9 (25) | 3 (10) | .088 | |
| IFRT | 20 (28) | 13 (36) | 7 (24) | ||
| ISRT | 33 (47) | 14 (39) | 19 (66) | ||
| RT (n = 65) | |||||
| 3-Dimensional | 39 (60) | 27 (75) | 12 (41) | .010 | |
| Intensity-modulated RT | 26 (40) | 9 (25) | 17 (59) | ||
| Radiation dose (n = 65) | |||||
| Median (range), Gy | 30.6 (21.6-40.0) | 36 (30-40) | 30.6 (21.6-40) | ||
| >30.6 Gy | 32 (49) | 26 (72) | 6 (21) | <.001 | |
| ≤30.6 Gy | 33 (51) | 10 (28) | 23 (79) | ||
| Death | |||||
| Yes | 6 (8) | 3 (8) | 2 (7) | 1 (17) | |
| No | 65 (92) | 33 (92) | 27 (93) | 5 (83) | |
| Relapse or progression | |||||
| Yes | 15 (21) | 8 (22) | 5 (17) | 2 (33) | |
| No | 56 (79) | 28 (78) | 24 (83) | 4 (67) | |
| Local relapse | |||||
| Yes | 2 (3) | 0 | 0 | 2 (33) | |
| No | 69 (97) | 36 (100) | 29 (100) | 4 (67) | |
| Distant relapse | |||||
| Yes | 13 (18) | 8 (22) | 5 (17) | 0 | |
| No | 58 (82) | 28 (78) | 24 (83) | 6 (100) | |
| Transformation | |||||
| Yes | 2 (3) | 1 (3) | 1 (3) | .876 | 0 |
| No | 69 (97) | 35 (97) | 28 (97) | ||
| Second malignancy | |||||
| Yes | 8 (11) | 3 (8) | 5 (17) | .277 | 0 |
| No | 63 (89) | 33 (92) | 24 (83) | 6 (100) | |
| Median follow-up (95% CI), y* | 6.1 (5.0-7.2) | 6.1 (3.3-8.9) | 4.4 (0.42–8.4) | .174 | 7.5 (4.0-11.0) |
Unless otherwise noted, all data are n (%).
P value for comparison of all 3 groups is .341.